Fairmount Funds Management’s Dianthus Therapeutics DNTH Stock Holding History

Fairmount Funds Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247M	Hold	2,537,191	–	–	16.35%	2
2026 Q1	$213M	Buy	2,537,191 +400,000	+19%	+$23.2M	15.38%	2
2025 Q4	$88.1M	Sell	2,137,191 -1,170,000	-35%	-$45.4M	6.7%	6
2025 Q3	$130M	Buy	3,307,191 +600,000	+22%	+$15.3M	11.71%	1
2025 Q2	$50.4M	Buy	2,707,191 +6,500	+0.2%	+$122K	6.53%	7
2025 Q1	$49M	Hold	2,700,691	–	–	7.6%	6
2024 Q4	$58.9M	Hold	2,700,691	–	–	5.85%	9
2024 Q3	$73.9M	Sell	2,700,691 -62,146	-2%	-$1.73M	6%	9
2024 Q2	$71.5M	Hold	2,762,837	–	–	8.08%	6
2024 Q1	$82.9M	Buy	2,762,837 +834,334	+43%	+$18.1M	9.03%	4
2023 Q4	$20.1M	Hold	1,928,503	–	–	2.12%	12
2023 Q3	$26.4M	Buy	+1,928,503	New	+$24.3M	3.17%	13

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fairmount Funds Management's DNTH Position: Q2 2026 in Review

Fairmount Funds Management held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 2,537,191 shares worth $247M. The position accounts for 16.35% of the portfolio, ranked #2.

Fairmount Funds Management first reported a position in DNTH in Q3 2023 and has held it in 12 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Fairmount Funds Management held 2,537,191 shares of Dianthus Therapeutics worth $247M as of Q2 2026.
Fairmount Funds Management left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 16.35% of Fairmount Funds Management's portfolio in Q2 2026, its #2 holding.
Fairmount Funds Management first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 12 quarters since.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.